K-CAB Tab.
- Indication
- 1. Treatment of Erosive Gastroesophageal Reflux Disease
2. Treatment of Non-Erosive Gastroesophageal Reflux Disease
3. Treatment of Gastric Ulcer
4. Eradication of H. pylori concurrently given with appropriate antibiotic therapy treatment in patients with peptic ulcer and/or chronic atrophic gastritis
5. Maintenance of Healing of Erosive Gastroesophageal Reflux Disease - 25mg once daily
6. Prevention of peptic ulcers associated with the administration of non-steroidal anti-inflammatory drugs (NSAIDs) - 25mg once daily - Ingredient
- Tegoprazan
-
Prescription drugs
-
New Chemical Entity
If you are not automatically taken to the page on product information, please visit the website of the Korean Ministry of Food and Drug Safety (nedrug.mfds.go.kr/) and use the search function.